Home > Healthcare > Pharmaceuticals > Finished Drug Form > Sulphonamides Market

Sulphonamides Market Share

Report ID: GMI9708
Published Date: May 2024
Report Format: PDF

Download Free Sample

Sulphonamides Market Share

The competitive landscape of the sulphonamides industry is characterized by the presence of key players focused on innovation, research, and strategic partnerships. Also, the market witnessed competition from generic drug manufacturers offering cost-effective alternatives. The collaboration and licensing agreements between pharmaceutical companies and academic institutions further intensify competition, driving advancements and market growth in the sulphonamides sector.

Sulphonamides Market Companies

Some of the prominent players operating in the sulphonamides industry include:

Allergan
Amneal Pharmaceuticals LLC
Aurobindo Pharma
Bausch & Lomb Incorporated
Cadila Pharmaceuticals Ltd.
Cipla Ltd.
Dr. Reddy’s Laboratories
F. Hoffmann-La Roche Ltd.
GSK PLC
Glenmark Pharma Ltd.
Lexine Technochem Pvt. Ltd.
Monarch Pharmaceuticals
Pfizer Inc.
Sun Pharmaceutical Industries Ltd.
Teva Pharmaceutical Industries Ltd.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The market size of sulphonamides was reached USD 122.4 million in 2023 and will grow at 4.8% CAGR from 2024 to 2032, driven by the increasing prevalence of infectious diseases globally.

The oral administration mode segment of the sulphonamides market recorded USD 66.2 million in 2023 and will reach USD 98.6 million by 2032, as it offers convenient administration, facilitating patient compliance and ensuring timely treatment initiation.

U.S. sulphonamides market size accounted for USD 48 million in 2023 and is anticipated to show significant growth, due to high prevalence and incidence of infectious diseases.

Aurobindo Pharma, Bausch & Lomb Incorporated, Cadila Pharmaceuticals Ltd, Cipla Ltd, Dr. Reddy’s Laboratories, F. Hoffmann-La Roche Ltd, GSK PLC, Glenmark Pharma Ltd, and Lexine Technochem Pvt. Ltd. among others.